Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.

ABSTRACT:

Importance

Preclinical data suggest that poly(ADP-ribose) polymerase (PARP) inhibitors have synergistic activity when combined with immune checkpoint inhibitors (ICIs); however, it is unknown which tumor types or molecular subtypes may benefit from this combination.

Objective

To investigate responses associated with the combination of avelumab and talazoparib in different tumor types and/or molecular subtypes.

Design, setting, and participants

In this phase 1b and 2 basket nonrandomized controlled trial, patients with advanced solid tumors were enrolled in the following cohorts: non-small cell lung cancer (NSCLC); DNA damage response (DDR)-positive NSCLC; triple-negative breast cancer (TNBC); hormone receptor-positive, human epidermal growth factor receptor 2 (ERBB2)-

SUBMITTER: Yap TA 

PROVIDER: S-EPMC9673022 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature